<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The study included 58 patients with CHD and <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo> divided into 2 groups depending on thyroid hormone and thyrotropin levels </plain></SENT>
<SENT sid="1" pm="."><plain>Group 1 was comprised of 24 patients with subclinical <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo>, group 2 of 18 ones with subclinical <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Control group consisted of l6 patients with CHD, <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> thvroid function </plain></SENT>
<SENT sid="3" pm="."><plain>It was shown that patients with CHD, <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo> and subclinical <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> had T3 and T4 levels 92.6 and 72.5% higher than those with subclinical <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Subclinical thyroid dysfunction was shown to influence hemodynamic isoelectric parameters of the heart </plain></SENT>
<SENT sid="5" pm="."><plain>Therapy of <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo> in CHD patients with subclinical <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> or <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo> with simultaneous correction of thyroid function increases the efficacy of anti-arrhythmic therapy up to 50 and 45.9% respectively </plain></SENT>
</text></document>